Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.81 USD | +0.71% | +4.84% | -1.06% |
Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
Financials (USD)
Sales 2024 * | 83.55M | Sales 2025 * | 77.08M | Capitalization | 15.64M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | 2M | EV / Sales 2024 * | 0.19 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.2 x |
P/E ratio 2024 * |
-1.26
x | P/E ratio 2025 * |
5.62
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.51% |
Latest transcript on Aytu BioPharma, Inc.
1 day | +0.71% | ||
1 week | +4.84% | ||
Current month | -7.57% | ||
1 month | -7.57% | ||
3 months | -0.36% | ||
6 months | -10.52% | ||
Current year | -1.06% |
Managers | Title | Age | Since |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 15-04-15 |
Jarrett Disbrow
FOU | Founder | 49 | 15-04-15 |
Mark Oki
DFI | Director of Finance/CFO | 55 | 22-01-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vivian Liu
BRD | Director/Board Member | 62 | 22-06-30 |
Jarrett Disbrow
FOU | Founder | 49 | 15-04-15 |
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 15-04-15 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 2.81 | +0.71% | 6,647 |
24-04-19 | 2.79 | 0.00% | 6,921 |
24-04-18 | 2.79 | -2.90% | 3,294 |
24-04-17 | 2.873 | +0.47% | 4,312 |
24-04-16 | 2.86 | +6.72% | 7,382 |
Delayed Quote Nasdaq, April 22, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.06% | 15.64M | |
+25.46% | 659B | |
+26.41% | 557B | |
-4.86% | 359B | |
+16.44% | 322B | |
+8.34% | 297B | |
+6.40% | 215B | |
+8.09% | 210B | |
-5.77% | 200B | |
-8.79% | 149B |
- Stock Market
- Equities
- AYTU Stock